INTELLIGENT BIO SOLUTIONS INC.

For the period ended Dec 31, 2025. Filed Feb 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2025 · Filed Feb 12, 2026

INBS$2.29+16.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Changes in Shareholders’ Equity

Additional · Other · Non- · Total
Common stock · Treasury stock · paid-in · Accumulated · comprehensive · controlling · shareholders’
	Shares	Amount	Shares	Amount	capital	deficit	income (loss)	interest	equity
Balance, June 30, 2025*	732,326	$7,323	(12)	$(1)	$65,849,823	$(62,533,065)	$(327,944)	$(182,312)	$2,813,824
Issuance of restricted stock to vendors	816	8	-	-	11,992	-	-	-	12,000
Issuance of common stock, net of issuance costs At-the- Market Offerings	12,326	123	-	-	213,627	-	-	-	213,750
Common stock issued for warrants exercised, net of issuance costs	164,367	1,644	-	-	3,331,987	-	-	-	3,333,631
Foreign currency translation adjustment	-	-	-	-	-	-	48,716	-	48,716
Net loss	-	-	-	-	-	(2,983,006)	-	(11,986)	(2,994,992)
Balance, September 30, 2025	909,835	9,098	(12)	(1)	69,407,429	(65,516,071)	(279,228)	(194,298)	3,426,929
Reverse stock split rounding adjustment	(1)	-	-	-	-	-	-	-	-
Issuance of restricted stock to vendors	9,236	92	-	-	61,483	-	-	-	61,575
Issuance of common stock, net of issuance costs At-the- Market Offerings	192,072	1,921	-	-	1,157,562	-	-	-	1,159,483
Common stock issued for warrants exercised, net of issuance costs	22,291	223	-	-	2,006	-	-	-	2,229
Issuance of common stock, net of issuance costs	105,000	1,050	-	-	8,912,009	-	-	-	8,913,059
Foreign currency translation adjustment	-	-	-	-	-	-	13,149	-	13,149
Net loss	-	-	-	-	-	(2,677,590)	-	(9,023)	(2,686,613)
Balance, December 31, 2025	1,238,434	$12,384	(12)	$(1)	$79,540,489	$(68,193,661)	$(266,079)	$(203,321)	$10,889,811

Common stock · Treasury stock · Additional paid-in · Accumulated · Other comprehensive · Non- controlling · Total shareholders’
	Shares	Amount	Shares	Amount	capital	deficit	income (loss)	interest	equity
Balance, June 30, 2024*	345,600	$3,456	(12)	$(1)	$61,002,841	$(51,964,332)	$(712,614)	$(146,159)	$8,183,191
Issuance of common stock upon exercise of warrants	79,393	794	-	-	7,145	-	-	-	7,939
Stock awards issued to employees	9,950	100	-	-	189,945	-	-	-	190,045
Issuance of restricted stock to vendors	1,116	11	-	-	11,989	-	-	-	12,000
Issuance of common stock, net of issuance costs At-the- Market Offerings	1,717	17	-	-	34,494	-	-	-	34,511
Foreign currency translation adjustment	-	-	-	-	-	-	216,355	-	216,355
Net loss	-	-	-	-	-	(2,685,633)	-	(9,166)	(2,694,799)
Balance, September 30, 2024	437,776	4,378	(12)	(1)	61,246,414	(54,649,965)	(496,259)	(155,325)	5,949,242
Issuance of restricted stock to vendors	811	8	-	-	11,992	-	-	-	12,000
Issuance of common stock, net of issuance costs At-the- Market Offerings	42,120	421	-	-	641,687	-	-	-	642,108
Foreign currency translation adjustment	-	-	-	-	-	-	(143,165)	-	(143,165)
Net loss	-	-	-	-	-	(2,249,470)	-	(7,327)	(2,256,797)
Balance, December 31, 2024	480,707	$4,807	(12)	$(1)	$61,900,093	$(56,899,435)	$(639,424)	$(162,652)	$4,203,388

*	Common stock and per share amounts have been retroactively adjusted to a 1-for-10 reverse stock split effected on December 15, 2025, throughout the condensed consolidated financial statements unless otherwise stated.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.